RET and thyroid cancer: After eligibility criteria were applied, a total of 68 patients with RET fusion-positive a/m NSCLC who initiated selpercatinib were obtained from the FHD, while 75 patients, including those having lung (57.3%, n = 43) or thyroid cancer (32.0%, n = 24), were identified from CDM (Figure 1).